Rigel Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

OTHER BALANCE SHEET

OTHER BALANCE SHEET

12 Months Ended

Dec. 31, 2020

OTHER BALANCE SHEET

OTHER BALANCE SHEET

9. OTHER BALANCE SHEET

Property and equipment consists of the following (in thousands):


	December 31,
	2020		2019
Laboratory equipment	$	11,957	$	11,627
Computer and software		1,783		1,622
Furniture and equipment		1,793		1,391
Fixed assets in progress		819		564
Total property and equipment		16,352		15,204
Less accumulated depreciation and amortization		(13,676)		(13,045)
Property and equipment, net	$	2,676	$	2,159

During 2020 and 2019, we disposed fixed assets of approximately $86,000 and $496,000, respectively.

Total depreciation and amortization expense were $706,000, $683,000 and $594,000 for the years ended December 31, 2020, 2019 and 2018, respectively.

Other accrued liabilities consists of the following (in thousands):


	December 31,
	2020		2019
Revenue reserves	$	4,576	$	3,094
Accrued expenses		3,661		2,836
Refund liability		1,488		238
Accrued professional fees		1,017		473
Accrued interest payable		272		80
Total	$	11,014	$	6,721

Revenue reserves include government-mandated or privately-negotiated rebates, chargebacks and discounts on our gross product sales. Accrued professional fees include legal and patent costs and accounting fees.